Business Wire10d
Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of ...
MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ALLEVIATE-2 Phase 3 pivotal ...
Indiatimes20d
TRIS: The Mother of All Search Engines on India’s Soul and Spirit
The Tuli Research Centre for India Studies has launched an extensive digital archive at www.tuliresearchcentre.org, capturing India's cultural essence through a unique range of artifacts.
pharmaphorum1d
Tris cues up filing for non-opioid pain drug on phase 3 win
Tris Pharma has set its sights on an FDA filing for pipeline drug cebranopadol before the end of this year after the drug achieved significant pain relief in abdominoplasty patients in a late ...
BioPharma Dive10d
Tris to ask for approval of dual-acting pain drug
On Thursday, Tris Pharma released data from a clinical trial of about 240 people who had undergone bunion removal, a notoriously painful operation. Results showed that, over a two-day period post ...